Fig. 8: SAH-JGZ4 sensitizes NSCLC to chemotherapy.

a Cell viability of A549 cells treated with different concentrations of carboplatin, pemetrexed, gemcitabine, or taxol in combination with 5 µM SAH-JGZ4 or SAH-Con for 72 h. Data are means ± SEM of three independent assays. b Cell viability of H1975 cells treated with different concentrations of carboplatin or pemetrexed in combination with 5 µM SAH-JGZ4 or SAH-Con for 72 h. Data are means ± SEM of three independent assays. c Schematic diagram for the construction of patient-derived tumor xenograft (PDX) models from NSCLC patients. Effects of carboplatin in combination with SAH-JGZ4 or SAH-Con on tumor growth (d) and survival (e) in the PDX-1# model. Effects of pemetrexed in combination with SAH-JGZ4 or SAH-Con on tumor growth (f) and survival (g) in the PDX-1# model. Effects of carboplatin in combination with SAH-JGZ4 or SAH-Con on tumor growth (h) and survival (i) in the PDX-2# model. Effects of pemetrexed in combination with SAH-JGZ4 or SAH-Con on tumor growth (j) and survival (k) in the PDX-2# model. Effects of TRIB3 deletion on tumor growth (l) and survival (m) in PDX-2# model. n Schematic diagram illustrates the molecular mechanism of how TRIB3 promoting EGFR recycling and stability, as well as NSCLC development. Statistical significance between two groups was determined with two-tailed Student’s t test. Data in d, f, h, j, and l are presented as means ± SEM. Statistical significance among groups was determined by one-way ANOVA test. Statistical differences for the survival in e, g, i, k, and m were determined by two-sided log-rank test. CBP carboplatin, PEM pemetrexed, GEM gemcitabine. Source data are provided as a Source Data file.